期刊
EXPERT REVIEW OF VACCINES
卷 20, 期 2, 页码 185-198出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2021.1878028
关键词
Transmission-blocking vaccine; malaria; herd immunity; mosquito; Plasmodium falciparum; Plasmodium vivax; surrogate assay; cluster-randomized trial
类别
Transmission-blocking vaccines target mosquito sexual stage parasites to prevent malaria spread, relying on herd immunity to reduce new infections but offering no protection post-infection. Clinical development faces challenges in ensuring durability and efficacy, with candidates in trials targeting specific antigens and exploring platforms and adjuvants for enhanced immunogenicity. Efficacy trials require special considerations to measure herd immunity and address confounding factors like human and mosquito movements.
Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in elimination programs. TBV rely on herd immunity to reduce mosquito infections and thereby new infections in both vaccine recipients and non-recipients, but do not provide protection once an individual receives an infectious mosquito bite which complicates clinical development. Areas covered Here, we describe the concept and biology behind TBV, and we provide an update on clinical development of the leading vaccine candidate antigens. Search terms 'malaria vaccine,' 'sexual stages,' 'transmission blocking vaccine,' 'VIMT' and 'SSM-VIMT' were used for PubMed queries to identify relevant literature. Expert opinion Candidates targeting P. falciparum zygote surface antigen Pfs25, and its P. vivax orthologue Pvs25, induced functional activity in humans that reduced mosquito infection in surrogate assays, but require increased durability to be useful in the field. Candidates targeting gamete surface antigens Pfs230 and Pfs48/45, respectively, are in or nearing clinical trials. Nanoparticle platforms and adjuvants are being explored to enhance immunogenicity. Efficacy trials require special considerations, such as cluster-randomized designs to measure herd immunity that reduces human and mosquito infection rates, while addressing human and mosquito movements as confounding factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据